Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris
Shuai Shao, Jiaoling Chen, William R. Swindell, Lam C. Tsoi, Xianying Xing, Feiyang Ma, Ranjitha Uppala, Mrinal K. Sarkar, Olesya Plazyo, Allison C. Billi, Rachael Wasikowski, Kathleen M. Smith, Prisca Honore, Victoria E. Scott, Emanual Maverakis, J. Michelle Kahlenberg, Gang Wang, Nicole L. Ward, Paul W. Harms, Johann E. Gudjonsson
Shuai Shao, Jiaoling Chen, William R. Swindell, Lam C. Tsoi, Xianying Xing, Feiyang Ma, Ranjitha Uppala, Mrinal K. Sarkar, Olesya Plazyo, Allison C. Billi, Rachael Wasikowski, Kathleen M. Smith, Prisca Honore, Victoria E. Scott, Emanual Maverakis, J. Michelle Kahlenberg, Gang Wang, Nicole L. Ward, Paul W. Harms, Johann E. Gudjonsson
View: Text | PDF
Research Article Dermatology Immunology

Phospholipase A2 enzymes represent a shared pathogenic pathway in psoriasis and pityriasis rubra pilaris

  • Text
  • PDF
Abstract

Altered epidermal differentiation along with increased keratinocyte proliferation is a characteristic feature of psoriasis and pityriasis rubra pilaris (PRP). However, despite this large degree of overlapping clinical and histologic features, the molecular signatures these skin disorders share are unknown. Using global transcriptomic profiling, we demonstrate that plaque psoriasis and PRP skin lesions have high overlap, with all differentially expressed genes in PRP relative to normal skin having complete overlap with those in psoriasis. The major common pathway shared between psoriasis and PRP involves the phospholipases PLA2G2F, PLA2G4D, and PLA2G4E, which were found to be primarily expressed in the epidermis. Gene silencing each of the 3 PLA2s led to reduction in immune responses and epidermal thickness both in vitro and in vivo in a mouse model of psoriasis, establishing their proinflammatory roles. Lipidomic analyses demonstrated that PLA2s affect mobilization of a phospholipid-eicosanoid pool, which is altered in psoriatic lesions and functions to promote immune responses in keratinocytes. Taken together, our results highlight the important role of PLA2s as regulators of epidermal barrier homeostasis and inflammation, identify PLA2s as a shared pathogenic mechanism between PRP and psoriasis, and as potential therapeutic targets for both diseases.

Authors

Shuai Shao, Jiaoling Chen, William R. Swindell, Lam C. Tsoi, Xianying Xing, Feiyang Ma, Ranjitha Uppala, Mrinal K. Sarkar, Olesya Plazyo, Allison C. Billi, Rachael Wasikowski, Kathleen M. Smith, Prisca Honore, Victoria E. Scott, Emanual Maverakis, J. Michelle Kahlenberg, Gang Wang, Nicole L. Ward, Paul W. Harms, Johann E. Gudjonsson

×

Figure 6

PLA2s modulate phospholipid/eicosanoid profiles in keratinocytes.

Options: View larger image (or click on image) Download as PowerPoint
PLA2s modulate phospholipid/eicosanoid profiles in keratinocytes.
(A) Pr...
(A) Principal component analysis performed based on the abundance of 266 phospholipid and eicosanoids in PLA2G2F- or PLA2G4D-overexpressing keratinocytes. (B) The average total eicosanoid abundance (± 1 SEM) in each group (n = 6/group). Data are expressed as pmol/mL supernatant. Groups without the same letter differ significantly from one another (P < 0.05; Fisher’s least significant difference). (C) The average total phospholipid abundance (± 1 SEM) in each group averaging across all phospholipid categories (LPC + PC + LPE + PE + LPI + PI + LPG + PG + LPS + PS + LPS + PA) (n = 6/group). LPC, lyso-phosphatidylcholine; PC, phosphatidylcholine; LPE, lyso-phosphatidylethanolamine; PE, phosphatidylethanolamine; PI, phosphatidylinositol; PG, phosphatidylglycerol; PS, phosphatidylserine; PA, phosphatidic acid. Data are expressed as normalized intensities and constitute relative abundances per 1 × 106 cells (relative to internal standards). (D) Phospholipids most strongly altered by PLA2G2F and PLA2G4D overexpression. (E) Changes in eicosanoid abundance following PLA2G2F siRNA knockdown and correlation with changes observed in PLA2G2F-overexpressing keratinocytes. (F) Lipids with most strongly altered abundance following PLA2G2F siRNA knockdown in keratinocytes. (G) Lipids with the most siRNA-dependent IL-17A and TNF responses. (H) Changes in eicosanoid abundance following PLA2G2F siRNA knockdown and correlation with changes observed in lesional (psoriasis, PP), uninvolved (PN), and normal (NN) skin biopsies. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001 by 1-way ANOVA (B and C) or Pearson’s correlation coefficient (H).

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts